Study validates development of cost-effective semi-quantitative diagnostic method with 90% sensitivity

In a study published in Journal of Blood Medicine, researchers analyzed 179 convalescent plasma units for the presence of SARS-CoV-2 IgG antibodies. This study was conducted to determine if an automated chemiluminescent SARS-CoV-2 IgG antibody assay platform can accurately quantify the number of binding antibodies present in donated convalescent plasma.

The study concluded:

The utility of automated antibody detection systems can be extended from simply a screening method to a semi-quantitative and quantitative functional antibody analysis
Chemiluminescent immunoassay equipment-derived numerical values can be used to reliably estimate the ELISA antibody titer
There was significant linear correlation between the CLIA S/Co values and ELISA IgG titers. This indicates that comparable antibody quantification can be reliably derived from the results of an automated antibody detection system
Incorporation of chemiluminescent-based methods can provide rapid, cost-effective means of identifying anti-SARS-CoV-2 antibody titers in donated plasma for use in the treatment of COVID-19 infection

At a Glance

179

Convalescent plasma units analyzed for the presence of SARS-CoV-2 IgG antibodies

90 %

Sensitivity in predicting a titer dilution of ≥1:1024 with an identified CLIA S/Co cutoff value of 8.2

82 %

Specificity in predicting a titer dilution of ≥1:1024 with an identified CLIA S/Co cutoff value of 8.2

To Read The Full Study: Click Here

Source: Mendoza, R., Silver, M., Zuretti, A., Christian, M., Das, B., Norin, A., Borgen, P., Libien, J., & Bluth, M. (2021). Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods. Journal of Blood Medicine, Volume 12, 157–164. https://doi.org/10.2147/jbm.s296730

Information addressed to health professionals. The products presented on this site are for professional use only, and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

© 2024 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

U.S. Government Users Restricted Rights - As per GSA ADP Schedule Contract with Beckman Coulter, Inc., the use, duplication or disclosure is restricted as follows: Beckman Coulter hereby authorizes user to copy those documents published on the World Wide Web by Beckman Coulter, for noncommercial use, and only within the user's organization. Except as expressly provided above, nothing contained herein shall be construed as granting any license or right under any Beckman Coulter copyright. Nothing contained herein shall be construed as granting by implication, estoppel or otherwise any license or right under any patent or trademark of Beckman Coulter or any third party.

Choose your country/region and language

Country or Region

Language

Study validates development of cost-effective semi-quantitative diagnostic method with 90% sensitivity

At a Glance

To Read The Full Study: Click Here